VPA inhibits renal cancer cell migration by targeting HDAC2 and down-regulating HIF-1α

Molecular Biology Reports

Volumn 41, Issue 3, 2014, Pages 1511-1518

  Yang, Feng Qiang ^a   Liu, Min ^a   Yang, Feng Ping ^b   Che, Jianping ^a   Li, Wei ^a   Zhai, Wei ^a   Wang, Guang Chun ^a   Zheng, Jun Hua ^a   Li, Xi ^c  

^a TONGJI UNIVERSITY   (China)

^b Xinjiang Province   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Histone deacetylase; Hypoxia inducible factor; Renal cell carcinoma; Valproic acid

Indexed keywords

HISTONE DEACETYLASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; HUMAN; HUMAN CELL; KIDNEY CANCER; PROTEIN EXPRESSION; RNA INTERFERENCE;

CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 2; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; VALPROIC ACID;

EID: 84896049978     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-013-2996-2     Document Type: Article

References (25)

1. Ji C, Li X, Zhang S et al (2011) Laparoscopic radiofrequency ablation of renal tumors: 32-month mean follow-up results of 106 patients. Urology 77(4):798-802
2. Iacovelli R, Lanoy E, Albiges L, Escudier B (2012) Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU Int 110(11):1747-1753
3. Vanharanta S, Shu W, Brenet F et al (2013) Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med 19(1):50-56
4. Giannini G, Cabri W, Fattorusso C, Rodriquez M (2012) Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med Chem 4(11):1439-1460
5. Dallavalle S, Pisano C, Zunino F et al (2012) Development and therapeutic impact of HDAC6-selective inhibitors. Biochem Pharmacol 84(6):756-765
6. Berendsen S, Broekman M, Seute T et al (2012) Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results. Expert Opin Investig Drugs 21(9):1391-1415
7. Cotto M, Cabanillas F, Tirado M et al (2010) Epigenetic therapy of lymphoma using histone deacetylase inhibitors. Clin Transl Oncol 12(6):401-409
8. Sermeus A, Michiels C (2011) Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis 2:e164
9. Iqbal MM, Sohhan T, Mahmud SZ (2001) The effects of lithium, valproic acid, and carbamazepine during pregnancy and lactation. J Toxicol Clin Toxicol 39(4):381-392 (Pubitemid 32776960)
10. Chen N, Chen LP, Zhang J et al (2012) Molecular characterization and expression analysis of three hypoxia-inducible factor alpha subunits, HIF-1α/2α/3α of the hypoxia-sensitive freshwater species, Chinese sucker. Gene 498(1):81-90
11. Schito L, Rey S, Tafani M et al (2012) Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc Natl Acad Sci USA 109(40):E2707-E2716
12. Richon VM (2010) Targeting histone deacetylases: development of vorinostat for the treatment of cancer. Epigenomics 2(3):457-465
13. Wang G, He J, Zhao J et al (2012) Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. PLoS One 7(12):e52095
14. McCormack E, Haaland I, Venås G et al (2012) Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia 26(5):910-917
15. Mamlouk S, Wielockx B (2012) Hypoxia-inducible factors as key regulators of tumor inflammation. Int J Cancer. doi:10.1002/ijc.27901
16. Edeline J, Rioux-Leclercq N (2008) Renal cell carcinoma and prognostic factors. Ann Pathol 28(5):374-380
17. Singh BN, Zhang G, Hwa YL et al (2010) Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther 10(6):935-954
18. Menegola E, Cappelletti G, Di Renzo F (2012) Epigenetic approaches and methods in developmental toxicology: role of HDAC inhibition in teratogenic events. Methods Mol Biol 889:373-383
19. Seuter S, Heikkinen S, Carlberg C (2013) Chromatin acetylation at transcription start sites and vitamin D receptor binding regions relates to effects of 1α,25-dihydroxyvitamin D3 and histone deacetylase inhibitors on gene expression. Nucleic Acids Res 41(1):110-124
20. Verheul HM, Salumbides B, Van Erp K et al (2008) Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 14(11):3589-3597
21. Geng H, Harvey CT, Pittsenbarger J et al (2011) HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia. J Biol Chem 286(44):38095-38102
22. Xu Y, Li Y, Li H et al (2013) The accumulations of HIF-1α and HIF-2α by JNK and ERK are involved in biphasic effects induced by different levels of arsenite in human bronchial epithelial cells. Toxicol Appl Pharmacol 266(2):187-197
23. Qian DZ, Kachhap SK, Collis SJ et al (2006) Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 66(17):8814-8821 (Pubitemid 44449199)
24. Kim MJ, Kim DE, Jeong IG et al (2012) HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells. Anticancer Res 32(8):3161-3168
25. Oddsson SJ, Hardarson S, Petursdottir V et al (2012) Synchronous pulmonary metastases from renal cell carcinoma - a whole nation study on prevalence and potential resectability. Scand J Surg 101(3):160-165